Zacks Investment Research downgraded shares of GTX INC (GTXI) from OUTPERFORM to NEUTRAL on January 12, 2015, with a target price of $0.90.
GTX Inc is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics primarily related to the treatment of serious men's health conditions. GTx's drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on GTX INC (GTXI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment